Biosimilars

Healthcare experts weigh in on the president’s plan to lower drug prices. Here’s what they said.

The new Bipartisan Budget Act of 2018 (to be in effect on January 2019) institute new reimbursement guidelines for biosimilars under the Medicare coverage gap discount program that remove disincentives for biosimilar uptake and level the playing field for the future market place.

Understanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.

The impact of VBRs on outcomes, VBRs versus other healthcare reimbursement initiatives, and VBR successes and failures. Pfizer’s Robert Popovian, PharmD, weighs in.

How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.

The next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.

Biosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.

Awareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study.

Biosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?